Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Regeneron Pharmaceuticals Inc    REGN   US75886F1075

Delayed Quote. Delayed Nasdaq - 04/24 04:00:00 pm
480.09 USD   +0.00%
04/10 REGENERON PHARM : to Report First Quarter 2015 Financial and Operati..
04/07 NASDAQ 100 MOVE : Viab, regn
03/27DJREGENERON PHARM : Correction on March 25 Regeneron Story
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/20/2015 04/21/2015 04/22/2015 04/23/2015 04/24/2015 Date
452.42(c) 463.22(c) 472.63(c) 480.08(c) 480.09(c) Last
346 602 1 177 517 978 730 1 070 759 905 249 Volume
+1.09% +2.39% +2.03% +1.58% 0.00% Change
More quotes
Financials ($)
Sales 2015 3 572 M
EBIT 2015 1 491 M
Net income 2015 587 M
Finance 2015 1 643 M
Yield 2015 -
Sales 2016 4 328 M
EBIT 2016 2 002 M
Net income 2016 885 M
Finance 2016 2 995 M
Yield 2016 -
PER 2015 96,24
PER 2016 65,54
EV / Sales 2015 13,2x
EV / Sales 2016 10,5x
Capitalization 48 636 M
More Financials
Company
Regeneron Pharmaceuticals, Inc. operates as a biopharmaceutical company.It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.Regeneron markets medicines for eye diseases, colorectal cancer and a rare inflammatory condition and... 
Sector
Pharmaceuticals
Calendar
05/07Earnings Release
More about the company
Surperformance© ratings of Regeneron Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
Latest news on REGENERON PHARMACEUTICALS
04/10 REGENERON PHARMACEUTICALS : to Report First Quarter 2015 Financial and Operating..
04/07 NASDAQ 100 MOVERS : Viab, regn
04/01 REGENERON PHARMACEUTICALS : EYLEA® aflibercept Injection Receives FDA Approval f..
03/27DJREGENERON PHARMACEUTICALS : Correction on March 25 Regeneron Story
03/26DJREGENERON PHARMACEUTICALS : Correction to Headline on Wednesday's Regeneron Stor..
03/26 REGENERON PHARMACEUTICALS : Assigned Patent
03/26 SANOFI : and Regeneron Release 18-Month Results of Odyssey Long Term Trial with ..
03/25DJRegeneron Wins Expanded Approval for Eye Drug Eylea
More news
Sector news : Pharmaceuticals - NEC
04/25 ABBVIE : Presents Late-Breaking, Preliminary Phase 3b Data with VIEKIRAX® + EXVI..
04/25 BRISTOL MYERS SQUIBB : ALLY-1 Trial Results Show Investigational Daclatasvir-Bas..
04/25 MERCK KGAA : Wins German Innovation Award with Liquid Crystals
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
04/22 A Discussion Of Amgen's Q1 Results, With Updates On Its Pipeline
04/15 Big Pharmas' Dirty Little Secret About Cholesterol Lowering Drugs
04/13 Earnings And GDP Temporarily Take Investor Spotlight Off The Fed
03/31 Strong Dollar Hurts Profit Forecasts In Long Term
03/30 Nonfarm Payrolls Will Be Closely Watched - Cramer's Mad Money (3/27/15)


Comments 
Advertisement
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals  Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Full-screen chart
Technical analysis trends
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF